Semaglutide May Slow Aging. Here Is What the New Nature Study Found.

💡 A University of California, Berkeley team reported in Nature that semaglutide, the active ingredient in Ozempic and Wegovy, extended median lifespan in older female mice by about 12 percent. Treated mice also showed better muscle function, memory, and blood sugar control, suggesting the drug may act on aging biology, not just body weight.

What Did the Berkeley Study Actually Find?

A UC Berkeley team, led by Danica Chen, treated 20-month-old female mice (roughly equivalent to women in their 60s) with semaglutide for at least three months, then followed them to end of life. The result, published in Nature (volume 657, 2026), was clear: mice on semaglutide lived a median of 834 days, compared to 742 days for untreated controls. That is roughly 100 extra days, a 12 percent increase in median lifespan.

Beyond raw survival time, the treated mice were noticeably healthier. They explored more, solved mazes faster, walked farther on a treadmill, and maintained stable blood sugar. Inflammation markers fell, and stem cell populations in bone marrow and brain tissue showed stronger regenerative capacity: signs that their bodies were aging more slowly at a functional level.

How Could a Weight-Loss Drug Affect Aging?

Semaglutide mimics a natural hormone called GLP-1 (glucagon-like peptide 1) that the gut releases after eating. It slows digestion, signals the brain to reduce hunger, and stabilizes blood sugar. These effects explain the weight loss that made Ozempic famous. If you are curious about how the drug interacts with the brain's hunger circuitry, an earlier post covers what Yale researchers found in 2026.

The Berkeley team found something deeper. Gene expression analysis showed patterns closely resembling caloric restriction, a well-established longevity intervention in animals. Inflammation genes quieted. Genes for blood sugar handling and protein maintenance stepped up. But crucially, the treated mice maintained normal metabolic rates, while calorie-restricted mice showed slowed metabolism. That suggests semaglutide aging effects operate through a pathway distinct from simply eating less. The precise molecular mechanism, researcher Danica Chen admitted, "is a mystery."

What Does This Mean for You if You Take Ozempic or Wegovy?

This post is general information, not medical advice. Talk to your doctor before starting or changing any medication.

Roughly 40 to 50 million people globally now use GLP-1 receptor agonists, mainly semaglutide or tirzepatide. If you are among them, this study offers a broader frame for what the drug may be doing beneath the weight-loss effect.

The clinical picture was already building before this paper. Earlier observational studies found GLP-1 users had lower rates of heart attack, stroke, chronic kidney disease, sleep apnea, and certain cancers. These connections seemed puzzling: why would a weight drug help so many unrelated conditions? A partial answer is forming. If semaglutide is acting on aging biology itself, a wide range of clinical benefits "is exactly what you would expect to see," as Rafael de Cabo of the NIH National Institute on Aging put it in response to the study.

This does NOT mean starting semaglutide for longevity reasons is supported by evidence today. But it does reframe what these drugs may be doing, and it gives researchers a specific mechanism to test in people.

The Honest Limits: Why Mice Are Not Humans

The study used only female mice. Longevity research in rodents often shows sex-specific effects, and there is no guarantee the findings apply equally to men or to other populations. The researchers did not test males, and acknowledged this gap explicitly.

More broadly, dozens of interventions have extended mouse lifespan over the decades without producing similar results in human trials. The authors stated plainly: "There is no indication that similar results could be immediately achieved in humans." Semaglutide also carries documented risks, including nausea, gastrointestinal effects, and potential muscle mass loss. Starting it purely for anti-aging, without medical supervision, is not something this evidence supports.

What to Watch Over the Next Few Years

The Berkeley team is calling for human clinical trials specifically designed to measure aging outcomes, not just weight or blood sugar. NIH's National Institute on Aging funds related work through its Interventions Testing Program, which runs controlled longevity trials before recommending human studies.

Two things are worth following: whether trials emerge testing GLP-1 drugs against biological aging markers (such as epigenetic clocks) in older healthy adults, and whether follow-up studies answer the male-mice question. Both will take several years. ScienceDaily coverage of the study notes that the Berkeley team is already pursuing follow-up work on the mechanism.

Semaglutide was licensed for diabetes, then weight loss, then cardiovascular risk reduction. Slowing aging itself would be the largest application yet. But that chapter is still being written, and this study is one of its first sentences.

FAQ

Source(s): Nature, "Late-life semaglutide treatment slows ageing and extends lifespan in female mice" (2026); ScienceDaily (2026); Scientific American (2026)

About the author

Dao Huy (Lucas) is a professional translator working across English, Vietnamese, Chinese, and French, with more than 7 years of experience in medical, legal, and technical translation. He follows developments in medicine and longevity research because understanding what science actually says, versus what gets oversimplified in headlines, is core to accurate translation and clear communication.

If you need English-Vietnamese translation for medical documents, clinical research materials, or pharmaceutical content, Lucas offers professional translation and localization services. Visit daohuy.com to request a quote.